Middle East Advanced Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test (Tumor Marker Tests, Imaging-Based Diagnostics), By End Use (Hospitals & Cancer Specialty Centers, Research & Academic Institutes), By Country, and Segment Forecas
Description
Market Size & Trends
The Middle East advanced cancer diagnostics market size was estimated at USD 1.32 billion in 2024 and is projected to reach USD 2.51 billion by 2030, growing at a CAGR of 7.30% from 2025 to 2033. The market for advanced cancer diagnostics in the Middle East is driven by several strong factors such as increasing prevalence of cancer, growing demand for early detection, launch of advanced diagnostic technologies, and investment under national healthcare modernization.
Breakthroughs such as liquid biopsy, AI-enabled pathology, and biomarker-driven companion diagnostics accelerate precision oncology, enabling more personalized and effective treatment. For instance, in June 2025, M42, AstraZeneca & SOPHiA GENETICS launched UAE liquid biopsy initiative to transform cancer care. As part of the collaboration, M42 will incorporate SOPHiA GENETICS' MSK-ACCESS, which is powered by SOPHiA DDM technology, into its testing infrastructure, allowing for non-invasive genomic profiling of cancers using a simple blood draw. This approach complements, not replaces, routine screenings and is designed for patients who are unable to undergo a solid tumor biopsy, allowing them to be matched with a precision therapy tailored to their specific cancer profile.
Further, governments across the country, particularly in the UAE, Qatar, and Saudi Arabia prioritize oncology care, implement national cancer control programs, and promote advanced diagnostic technologies like liquid biopsies, next-generation sequencing (NGS), and molecular imaging. Furthermore, the increasing number of specialized cancer centers and international collaborations hastened the adoption of precision diagnostics. Also, private sector participation and partnership with Middle East diagnostic firms improve access to cutting-edge tools and expertise.
Rapid technological advancements, evolving policy frameworks, and shifting healthcare priorities influence the market dynamics for advanced cancer diagnosis. Traditionally, cancer diagnosis and treatment were primarily determined by tumor location and stage, but the advent of advanced diagnostics has altered this paradigm. These new technologies provide detailed insights into cancer's molecular, genetic, and biological underpinnings, making precision medicine a reality. Advanced diagnostics reduce the likelihood of incorrect diagnoses while allowing for more personalized treatment selection. This precision reduces patient exposure to ineffective therapies and their associated side effects, while also allowing for real-time monitoring of treatment outcomes.
Public-private partnerships and collaborations, increasing adoption of precision medicine, and favorable reimbursement policies facilitating broader adoption of advanced diagnostic technologies are fueling market's growth. For instance, in March 2025, Lunit expanded its partnership with Saudi Arabia's largest medical group to deploy an AI Chest X-Ray Solution. This latest contract expands on Lunit's previous collaboration with HMG, which introduced Lunit INSIGHT MMG to support breast cancer screening across the Kingdom. The collaboration between Lunit and INSIGHT CXR aimed to improve diagnostic accuracy and efficiency in detecting critical chest abnormalities like lung cancer, pneumonia, and tuberculosis.
Favorable reimbursement policies and regulatory alignment, such as Saudi Arabia's Vision 2030 healthcare reforms and insurance expansions, contribute to the rapid adoption of advanced diagnostics. Furthermore, PPP-funded national awareness campaigns, technology transfer initiatives improve Country access, affordability of advanced diagnostic tools, and clinician training programs. The UAE's breast cancer diagnostics industry exemplifies this by leveraging public-private partnerships, AI-powered imaging, and liquid biopsy programs to improve early detection and precision treatment.
Middle East Advanced Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, Grand View Research has segmented the Middle East advanced cancer diagnostics market report by test, end use, and country:
The Middle East advanced cancer diagnostics market size was estimated at USD 1.32 billion in 2024 and is projected to reach USD 2.51 billion by 2030, growing at a CAGR of 7.30% from 2025 to 2033. The market for advanced cancer diagnostics in the Middle East is driven by several strong factors such as increasing prevalence of cancer, growing demand for early detection, launch of advanced diagnostic technologies, and investment under national healthcare modernization.
Breakthroughs such as liquid biopsy, AI-enabled pathology, and biomarker-driven companion diagnostics accelerate precision oncology, enabling more personalized and effective treatment. For instance, in June 2025, M42, AstraZeneca & SOPHiA GENETICS launched UAE liquid biopsy initiative to transform cancer care. As part of the collaboration, M42 will incorporate SOPHiA GENETICS' MSK-ACCESS, which is powered by SOPHiA DDM technology, into its testing infrastructure, allowing for non-invasive genomic profiling of cancers using a simple blood draw. This approach complements, not replaces, routine screenings and is designed for patients who are unable to undergo a solid tumor biopsy, allowing them to be matched with a precision therapy tailored to their specific cancer profile.
Further, governments across the country, particularly in the UAE, Qatar, and Saudi Arabia prioritize oncology care, implement national cancer control programs, and promote advanced diagnostic technologies like liquid biopsies, next-generation sequencing (NGS), and molecular imaging. Furthermore, the increasing number of specialized cancer centers and international collaborations hastened the adoption of precision diagnostics. Also, private sector participation and partnership with Middle East diagnostic firms improve access to cutting-edge tools and expertise.
Rapid technological advancements, evolving policy frameworks, and shifting healthcare priorities influence the market dynamics for advanced cancer diagnosis. Traditionally, cancer diagnosis and treatment were primarily determined by tumor location and stage, but the advent of advanced diagnostics has altered this paradigm. These new technologies provide detailed insights into cancer's molecular, genetic, and biological underpinnings, making precision medicine a reality. Advanced diagnostics reduce the likelihood of incorrect diagnoses while allowing for more personalized treatment selection. This precision reduces patient exposure to ineffective therapies and their associated side effects, while also allowing for real-time monitoring of treatment outcomes.
Public-private partnerships and collaborations, increasing adoption of precision medicine, and favorable reimbursement policies facilitating broader adoption of advanced diagnostic technologies are fueling market's growth. For instance, in March 2025, Lunit expanded its partnership with Saudi Arabia's largest medical group to deploy an AI Chest X-Ray Solution. This latest contract expands on Lunit's previous collaboration with HMG, which introduced Lunit INSIGHT MMG to support breast cancer screening across the Kingdom. The collaboration between Lunit and INSIGHT CXR aimed to improve diagnostic accuracy and efficiency in detecting critical chest abnormalities like lung cancer, pneumonia, and tuberculosis.
Favorable reimbursement policies and regulatory alignment, such as Saudi Arabia's Vision 2030 healthcare reforms and insurance expansions, contribute to the rapid adoption of advanced diagnostics. Furthermore, PPP-funded national awareness campaigns, technology transfer initiatives improve Country access, affordability of advanced diagnostic tools, and clinician training programs. The UAE's breast cancer diagnostics industry exemplifies this by leveraging public-private partnerships, AI-powered imaging, and liquid biopsy programs to improve early detection and precision treatment.
Middle East Advanced Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, Grand View Research has segmented the Middle East advanced cancer diagnostics market report by test, end use, and country:
- Test Outlook (Revenue, USD Billion, 2021 - 2033)
- Tumor Marker Tests
- Fine Needle Aspiration Cytology (FNAC) & Biopsy
- Imaging-Based Diagnostics
- Bone Marrow Aspiration & Biopsy
- Immunohistochemistry (IHC) & Molecular Testing
- Genetic Testing for Cancer
- Liquid Biopsy
- End Use Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospitals & Cancer Specialty Centers
- Diagnostic Laboratories (Independent & Reference Labs)
- Research & Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Others
- Country Outlook (Revenue, USD Billion, 2021 - 2033)
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar
- Rest of Middle East
Table of Contents
130 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Market Definitions
- 1.2. Country Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Test Snapshot
- 2.3. End Use Snapshot
- 2.4. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.4. Business Environment Analysis
- 3.4.1. PESTLE Analysis
- 3.4.2. Porter’s Five Forces Analysis
- 3.5. COVID-19 Impact Analysis
- Chapter 4. Technique Business Analysis
- 4.1. Middle East Advanced Cancer Diagnostics Market: Test Movement Analysis, 2024 & 2033
- 4.2. Tumor Marker Tests
- 4.2.1. Tumor Marker Tests Market, 2021 - 2033 (USD Billion)
- 4.3. Fine Needle Aspiration Cytology (FNAC) & Biopsy
- 4.3.1. Fine Needle Aspiration Cytology (FNAC) & Biopsy market, 2021 - 2033 (USD Billion)
- 4.4. Imaging-Based Diagnostics
- 4.4.1. Imaging-Based Diagnostics market, 2021 - 2033 (USD Billion)
- 4.5. Bone Marrow Aspiration & Biopsy
- 4.5.1. Bone Marrow Aspiration & Biopsy market, 2021 - 2033 (USD Billion)
- 4.6. Immunohistochemistry (IHC) & Molecular Testing
- 4.6.1. Immunohistochemistry (IHC) & Molecular Testing market, 2021 - 2033 (USD Billion)
- 4.7. Genetic Testing
- 4.7.1. Genetic Testing Market, 2021 - 2033 (USD Billion)
- 4.8. Liquid Biopsy
- 4.8.1. Liquid Biopsy Market, 2021 - 2033 (USD Billion)
- Chapter 5. End Use Business Analysis
- 5.1. Middle East Advanced Cancer Diagnostics Market: End Use Movement Analysis, 2024 & 2033
- 5.2. Hospitals & Cancer Specialty Centers
- 5.2.1. Hospitals & Cancer Specialty Centers Market, 2021 - 2033 (USD Billion)
- 5.3. Diagnostic Laboratories
- 5.3.1. Diagnostic Laboratories market, 2021 - 2033 (USD Billion)
- 5.4. Research & Academic Institutes
- 5.4.1. Research & Academic Institutes market, 2021 - 2033 (USD Billion)
- 5.5. Pharmaceutical & Biotechnology Companies
- 5.5.1. Pharmaceutical & Biotechnology Companies market, 2021 - 2033 (USD Billion)
- 5.6. Others
- 5.6.1. Others Institutes market, 2021 - 2033 (USD Billion)
- Chapter 6. Country Business Analysis
- 6.1. Country Market Snapshot
- 6.2. Saudi Arabia
- 6.2.1. Saudi Arabia Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
- 6.2.2. UAE
- 6.2.2.1. UAE Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
- 6.2.2.2. Key Country Dynamics
- 6.2.2.3. Regulatory Framework
- 6.2.2.4. Competitive Scenario
- 6.2.3. Kuwait
- 6.2.3.1. Kuwait Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
- 6.2.3.2. Key Country Dynamics
- 6.2.3.3. Regulatory Framework
- 6.2.3.4. Competitive Scenario
- 6.2.4. Oman
- 6.2.4.1. Oman Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
- 6.2.4.2. Key Country Dynamics
- 6.2.4.3. Regulatory Framework
- 6.2.4.4. Competitive Scenario
- 6.2.5. Qatar
- 6.2.5.1. Qatar Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
- 6.2.5.2. Key Country Dynamics
- 6.2.5.3. Regulatory Framework
- 6.2.5.4. Competitive Scenario
- 6.2.6. Rest of Middle East
- 6.2.6.1. Rest of Middle East Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
- 6.2.6.2. Key Country Dynamics
- 6.2.6.3. Regulatory Framework
- 6.2.6.4. Competitive Scenario
- Chapter 7. Competitive Landscape
- 7.1. Market Participant Categorization
- 7.1.1. Market Leaders
- 7.1.2. Emerging Players
- 7.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
- 7.3. Company Profiles
- 7.3.1. Roche Diagnostics
- 7.3.1.1. Participant’s Overview
- 7.3.1.2. Financial Performance
- 7.3.1.3. Product/Service Benchmarking
- 7.3.1.4. Strategic Initiatives
- 7.3.2. Illumina, Inc.
- 7.3.2.1. Participant’s Overview
- 7.3.2.2. Financial Performance
- 7.3.2.3. Product/Service Benchmarking
- 7.3.2.4. Strategic Initiatives
- 7.3.3. Thermo Fisher Scientific
- 7.3.3.1. Participant’s Overview
- 7.3.3.2. Financial Performance
- 7.3.3.3. Product/Service Benchmarking
- 7.3.3.4. Strategic Initiatives
- 7.3.4. Siemens Healthineers
- 7.3.4.1. Participant’s Overview
- 7.3.4.2. Financial Performance
- 7.3.4.3. Product/Service Benchmarking
- 7.3.4.4. Strategic Initiatives
- 7.3.5. GE HealthCare
- 7.3.5.1. Participant’s Overview
- 7.3.5.2. Financial Performance
- 7.3.5.3. Product/Service Benchmarking
- 7.3.5.4. Strategic Initiatives
- 7.3.6. Philips Healthcare
- 7.3.6.1. Participant’s Overview
- 7.3.6.2. Financial Performance
- 7.3.6.3. Product/Service Benchmarking
- 7.3.6.4. Strategic Initiatives
- 7.3.7. Canon Medical Systems
- 7.3.7.1. Participant’s Overview
- 7.3.7.2. Financial Performance
- 7.3.7.3. Product/Service Benchmarking
- 7.3.7.4. Strategic Initiatives
- 7.3.8. Fujifilm Holdings Corporation
- 7.3.8.1. Participant’s Overview
- 7.3.8.2. Financial Performance
- 7.3.8.3. Product/Service Benchmarking
- 7.3.8.4. Strategic Initiatives
- 7.3.9. Agilent Technologies
- 7.3.9.1. Participant’s Overview
- 7.3.9.2. Financial Performance
- 7.3.9.3. Product/Service Benchmarking
- 7.3.9.4. Strategic Initiatives
- 7.3.10. Bruker Corporation
- 7.3.10.1. Participant’s Overview
- 7.3.10.2. Financial Performance
- 7.3.10.3. Product/Service Benchmarking
- 7.3.10.4. Strategic Initiatives
- 7.3.11. Becton, Dickinson and Company (BD)
- 7.3.11.1. Participant’s Overview
- 7.3.11.2. Financial Performance
- 7.3.11.3. Product/Service Benchmarking
- 7.3.11.4. Strategic Initiatives
- 7.3.12. Bio-Rad Laboratories
- 7.3.12.1. Participant’s Overview
- 7.3.12.2. Financial Performance
- 7.3.12.3. Product/Service Benchmarking
- 7.3.12.4. Strategic Initiatives
- 7.3.13. Myriad Genetics
- 7.3.13.1. Participant’s Overview
- 7.3.13.2. Financial Performance
- 7.3.13.3. Product/Service Benchmarking
- 7.3.13.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
